<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45332">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02051426</url>
  </required_header>
  <id_info>
    <org_study_id>112-06</org_study_id>
    <nct_id>NCT02051426</nct_id>
  </id_info>
  <brief_title>Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans</brief_title>
  <acronym>NMDAR</acronym>
  <official_title>Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzog Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herzog Hospital</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of compounds having agonistic activity at the glycine site associated with the
      N-methyl-D-aspartate receptor (NMDAR) is presently assessed in psychiatric disorders. In
      contrast to NMDAR antagonists, the neuropsychiatric effects of NMDAR agonists in the healthy
      human organism are not known. The investigators studied neuropsychiatric and neurochemical
      effects of the NMDAR-glycine site obligatory co-agonist D-serine (DSR) in healthy subjects
      using a randomized, controlled crossover challenge design including a baseline assessment
      day and two DSR/placebo administration days. Thirty-five subjects aged 23-29 years
      participated in the study and received a 2.1g orally administered DSR dose. The main outcome
      measures were the changes in scores of mood-related Visual Analogue Scale (VAS), Continuous
      Performance Test - Identical Pairs (CPT-IP), and Rey Auditory Verbal Learning Test (RAVLT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>changes in scores of mood-related Visual Analogue Scale (VAS)</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in scores of  Continuous Performance Test - Identical Pairs (CPT-IP)</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in scores of  Rey Auditory Verbal Learning Test (RAVLT)</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>single D-serine administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single P.O. administration of D-serine (30mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single Placebo administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>corn starch</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>single P.O. administration of D-serine (30mg/kg)</intervention_name>
    <arm_group_label>single D-serine administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>single Placebo administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

        Exclusion Criteria:

          -  history of psychiatric, medical, neurological illness or substance abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raz Levin, M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzog Hospital</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropsychiatric effects</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
